PHILADELPHIA, PA—New inclisiran data presented here show safety and efficacy in patients with familial hypercholesterolemia (FH) regardless of underlying genotype. The investigational, twice-yearly ...

SCTIMST performs its first LDL apheresis for Familial Hypercholesterolemia, dramatically lowering cholesterol in a 34-year-old patient.

Further reassurance about lowering LDL cholesterol and the risk for intracranial hemorrhage (ICH) in stroke patients has come from a new analysis of the Treat Stroke to Target (TST) trial. The ...

One and done? Pharma giant Eli Lilly announced Monday that its gene-editing therapy can reduce LDL (“bad”) cholesterol by up ...

Patients with refractory familial hypercholesterolemia that cannot be controlled with statins and PCSK9 inhibitors appeared to respond to evinacumab, a novel, fully human monoclonal antibody that ...

Please provide your email address to receive an email when new articles are posted on . Obicetrapib significantly lowered LDL vs. placebo in patients with heterozygous FH or ASCVD with uncontrolled ...

Please provide your email address to receive an email when new articles are posted on . Among patients who underwent PCI, an LDL level of 70 mg/dL or more was associated with elevated risk for ...

In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is ...